Company Description
Karyopharm Therapeutics Inc., a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases in the United States.
The company discovers, develops, and commercializes novel and small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein exportin 1 (XPO1).
Its lead compound, include XPOVIO in combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma; in combination with dexamethasone for the treatment of adult patients with relapsed or refractory multiple myeloma; and for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL).
It also developing Selinexor for treating hematological and solid tumor malignancies, including multiple myeloma, endometrial cancer, myelofibrosis, and DLBCL; and ELTANEXOR for treating Myelodysplastic Neoplasms, as well as verdinexor, KPT-9274, and IL-12 compounds.
The company has license agreement with Menarini Group to develop and commercialize selinexor for human oncology indications; license agreement with Antengene Therapeutics Limited to develop and commercialize selinexor, eltanexor, and KPT-9274 for the treatment and/or prevention of human oncology indications, as well as verdinexor for the diagnosis, treatment, and/or prevention of human non-oncology indications; and distribution agreement for the commercialization of XPOVIO with FORUS Therapeutics Inc. Further, it has a collaboration with Bristol Myers Squibb company to evaluate novel cereblon E3 ligase modulator agent mezigdomide in combination with Selinexor in patients with relapsed/refractory multiple myeloma.
Karyopharm Therapeutics Inc. was incorporated in 2008 and is headquartered in Newton, Massachusetts.
| Country | United States |
| Founded | 2008 |
| IPO Date | Nov 6, 2013 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 325 |
| CEO | Richard Paulson |
Contact Details
Address: 85 Wells Avenue, Suite 210 Newton, Massachusetts 02459-3298 United States | |
| Phone | 617 658 0600 |
| Website | karyopharm.com |
Stock Details
| Ticker Symbol | KPTI |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001503802 |
| CUSIP Number | 48576U106 |
| ISIN Number | US48576U1060 |
| Employer ID | 26-3931704 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Richard A. Paulson M.B.A. | President, Chief Executive Officer and Director |
| Sohanya Cheng M.B.A. | Executive Vice President, Chief Commercial Officer and Head of Business Development |
| Stuart Poulton | Executive Vice President and Chief Development Officer |
| Dr. Reshma Rangwala M.D., Ph.D. | Executive Vice President, Chief Medical Officer and Head of Research |
| Dr. Mansoor Raza Mirza M.D. | Clinical Consultant, Member of Scientific Advisory Board and Independent Director |
| Dr. Sharon Shacham M.B.A., Ph.D. | Co-Founder and Chairman of Scientific Advisory Board |
| Kristin Abate | Vice President, Chief Accounting Officer, Interim Principal Financial Officer and Assistant Treasurer |
| Brendan Twohig Strong | SVice President of Investor Relations and Corporate Communications |
| Michael J. Mano J.D. | Senior Vice President, General Counsel and Secretary |
| James Accumanno J.D. | Chief Compliance Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Dec 16, 2024 | DEF 14A | Other definitive proxy statements |
| Dec 5, 2024 | PRE 14A | Other preliminary proxy statements |
| Dec 3, 2024 | 8-K | Current Report |
| Nov 20, 2024 | 8-K | Current Report |
| Nov 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Nov 12, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Nov 8, 2024 | 8-K | Current Report |
| Nov 5, 2024 | S-8 | Securities to be offered to employees in employee benefit plans |
| Nov 5, 2024 | 10-Q | Quarterly Report |
| Nov 5, 2024 | 8-K | Current Report |